Russia unveils ‘Anti-aging Vaccine’: A gene therapy targeting cellular decay

Russia has announced a major breakthrough with the introduction of an “anti-aging vaccine.’ This gene therapy aims to slow cellular decay by blocking the RAGE receptor, a key trigger for age-related changes in the human body. 

Researchers have successfully conducted experimental procedures specifically designed to inhibit this receptor and halt the biological processes that drive aging.

The project is being developed by the Institute of Aging Biology and Medicine as part of Russia's significant push to expand domestic biotechnology research. 

This initiative directly addresses the economic and social challenges posed by Russia’s shrinking and aging population.

To this end, Russian officials have framed longevity research as both a public health priority and a matter of national security. The Kremlin continues to promote scientific programs aimed at expanding healthy life expectancy and ensuring the long-term vitality of the nation.

“The RAGE gene is a receptor whose activation launches the aging of the cell. Blocking this gene, on the contrary, can prolong its youth,” Sekirinsky said at a healthy longevity conference in the Volga city of Saransk, according to the state-run TASS news agency.

Deputy Prime Minister Tatyana Golikova stated that Russia plans to introduce an anti-ageing drug between 2028 and 2030. Under the umbrella of the “New Technologies for Health Preservation" national project launched in 2025; the program has a budget of more than 2 trillion rubles ($26.4 billion). 

 According to sources close to the Kremlin, the project was championed by Mikhail Kovalchuk who has been described as having an obsession with eternal life and the “genome of the Russian person”.

Furthermore, the recent announcement reflects the intensifying global scientific competition, with nations investing heavily in gene editing, regenerative medicine and technologies aimed at expanding health span. If this research proves successful, Russia could emerge as a significant player in the global anti-ageing medicine sector.